Personalized therapy: can it tame the COVID-19 monster?

被引：4
作者：
Arish, Mohd [1 ,2 ]
Naz, Farha [3 ]
机构：
[1] Jamia Hamdard, JH Inst Mol Med, New Delhi, India
[2] Mayo Clin, Dept Immunol, Div Pulm & Crit Care Med, Rochester, MN 55902 USA
[3] Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci CIRBSc, New Delhi, India
来源：
PERSONALIZED MEDICINE | 2021年 / 18卷 / 06期
关键词：
adverse effects; antivirals; biomarkers; COVID-19; drug repurposing; drugs; drug toxicity; personalized medicine; precision therapy; SARS-CoV-2; CONVALESCENT PLASMA THERAPY; CORONAVIRUS; HYDROXYCHLOROQUINE; CHLOROQUINE; ASSOCIATION; INFECTION; INHIBITOR;
D O I：
10.2217/pme-2021-0077
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
SARS-CoV-2, a recently emerged zoonotic virus, has resulted in unstoppable high morbidity and mortality rates worldwide. However, due to a limited knowledge of the dynamics of the SARS-CoV-2 infection, it has been observed that the current COVID-2019 therapy has led to some clinical repercussions. We discuss the adverse effects of drugs for COVID-2019 primarily based on some clinical trials. As therapeutic efficacy and toxicity of therapy may vary due to different, genetic determinants, sex, age and the ethnic background of test subjects, hence biomarker-based personalized therapy could be more appropriate. We will share our thoughts on the current landscape of personalized therapy as a roadmap to fight against SARS-CoV-2 or another emerging pathogen.
引用
收藏
页码：583 / 593
页数：11
相关论文
共 76 条
  • [1] Machine learning approaches to drug response prediction: challenges and recent progress
    Adam, George
    Rampasek, Ladislav
    Safikhani, Zhaleh
    Smirnov, Petr
    Haibe-Kains, Benjamin
    Goldenberg, Anna
    [J]. NPJ PRECISION ONCOLOGY, 2020, 4 (01)
  • [2] Tocilizumab for the treatment of severe coronavirus disease 2019
    Alattar, Rand
    Ibrahim, Tawheeda B. H.
    Shaar, Shahd H.
    Abdalla, Shiema
    Shukri, Kinda
    Daghfal, Joanne N.
    Khatib, Mohamed Y.
    Aboukamar, Mohamed
    Abukhattab, Mohamed
    Alsoub, Hussam A.
    Almaslamani, Muna A.
    Omrani, Ali S.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (10) : 2042 - 2049
  • [3] Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs
    Badary, Osama A.
    [J]. PHARMACOGENOMICS JOURNAL, 2021, 21 (03) : 275 - 284
  • [4] Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
    Blanco-Melo, Daniel
    Nilsson-Payant, Benjamin E.
    Liu, Wen-Chun
    Uhl, Skyler
    Hoagland, Daisy
    Moller, Rasmus
    Jordan, Tristan X.
    Oishi, Kohei
    Panis, Maryline
    Sachs, David
    Wang, Taia T.
    Schwartz, Robert E.
    Lim, Jean K.
    Albrecht, Randy A.
    tenOever, Benjamin R.
    [J]. CELL, 2020, 181 (05) : 1036 - +
  • [5] Immune determinants of COVID-19 disease presentation and severity
    Brodin, Petter
    [J]. NATURE MEDICINE, 2021, 27 (01) : 28 - 33
  • [6] The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
    Caly, Leon
    Druce, Julian D.
    Catton, Mike G.
    Jans, David A.
    Wagstaff, Kylie M.
    [J]. ANTIVIRAL RESEARCH, 2020, 178
  • [7] Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes Systematic Review and Meta-analysis
    Cano, Edison J.
    Fuentes, Xavier Fonseca
    Campioli, Cristina Corsini
    O'Horo, John C.
    Abu Saleh, Omar
    Odeyemi, Yewande
    Yadav, Hemang
    Temesgen, Zelalem
    [J]. CHEST, 2021, 159 (03) : 1019 - 1040
  • [8] Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]
  • [9] The convalescent sera option for containing COVID-19
    Casadevall, Arturo
    Pirofski, Liise-Anne
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04) : 1545 - 1548
  • [10] The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
    Chaccour, Carlos
    Casellas, Aina
    Blanco-Di Matteo, Andres
    Pineda, Inigo
    Fernandez-Montero, Alejandro
    Ruiz-Castillo, Paula
    Richardson, Mary-Ann
    Rodriguez-Mateos, Mariano
    Jordan-Iborra, Carlota
    Brew, Joe
    Carmona-Torre, Francisco
    Giraldez, Miriam
    Laso, Ester
    Gabaldon-Figueira, Juan C.
    Dobano, Carlota
    Moncunill, Gemma
    Yuste, Jose R.
    Del Pozo, Jose L.
    Rabinovich, N. Regina
    Schoening, Verena
    Hammann, Felix
    Reina, Gabriel
    Sadaba, Belen
    Fernandez-Alonso, Mirian
    [J]. ECLINICALMEDICINE, 2021, 32
12345678